Nexentis Technologies Inc.
NXTSAbout the company
Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. It operates through two segments, Biotechnology Activity and Renewable Energy Projects.
Investment snapshot
Positive
1
BUY / PASS
Neutral / negative
2 / 13
NEUTRAL / FAIL
Median fair value
—
No comparable estimates
Models with upside
0 / 17
Positive margin of safety
Key risk
No clean pass — all 13 investors flag at least one valuation criterion
Framework analysis
| Verdict | Meaning |
|---|---|
| BUY | Positive purchase signal: the framework's buy requirements are met. |
| PASS | The company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state. |
| NEUTRAL | Neither a positive nor negative conclusion. It does not mean to hold an existing position. |
| FAIL | The company does not clear the framework's requirements. |
| Ranked | Ranked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL. |
Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.
| Metric | Graham Defensive Value | Buffett Quality Compounder | Lynch GARP | Greenblatt Magic Formula | Piotroski F-Score | Dreman Contrarian Value | Munger Quality Focus | Pabrai Dhandho Framework | Akre Three-Legged Stool | Marks Risk-Aware Value | Ackman Activist Value | Templeton Global Bargain Hunter | Sleep Scale Economies Shared | Asness Systematic Factors | Neff Low-P/E Total Return | Schloss Asset-Value Discipline | O'Shaughnessy Systematic Factor Composite |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verdict | FAIL | FAIL | FAIL | Not ranked | PASS | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | NEUTRAL | FAIL | FAIL | NEUTRAL |
| Score | |||||||||||||||||
| Analysis | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… |
| Intrinsic Value (annual) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Margin of Safety | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financial Basis | Annual history · FY 2025 · Balance sheet at 2026-06-30 Latest source filing: 2026-08-13 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-31 Score computed: 2026-11-14 | Annual history · FY 2025 · Balance sheet at 2026-06-30 · TTM ended 2026-06-30 Latest source filing: 2026-08-13 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-31 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-31 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Market data at 2026-11-01 Latest source filing: 2026-08-13 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 Latest source filing: 2026-08-13 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 Latest source filing: 2026-03-31 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment · Balance sheet at 2026-06-30 Latest source filing: 2026-08-13 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-03-31 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Market data at 2026-11-01 Latest source filing: 2026-08-13 Score computed: 2026-11-14 | Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-06-30 Latest source filing: 2026-08-13 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-03-31 Score computed: 2026-11-14 | TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025 Latest source filing: 2026-08-13 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-31 Score computed: 2026-11-14 | Annual history · FY 2025 · Balance sheet at 2026-06-30 Latest source filing: 2026-08-13 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-06-30 · Price history 2025-01-01–2026-11-01 Latest source filing: 2026-08-13 Score computed: 2026-11-14 |
Where It Passes
Where It Falls Short
- Valuation0% pass✓ 6✗ 22▾
No clean pass — all 13 investors flag at least one valuation criterion
Price / 3-yr avg EPS✗Graham<= 15xPrice-to-Book Ratio0.4x✓Graham<= 1.5xP/E x P/B✗Graham<= 22.5Basic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)EBIT / Enterprise ValueN/A (EV <= 0)✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=N/A (EV <= 0), ROC=-546.5%✗GreenblattBoth EY > 10% and ROC > 25%Price / EPS✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)Price / (CFO / Shares)N/A (negative CFPS)✗Dreman< 8xPrice / Book Value per Share0.4x✓Dreman< 1.2x✓Templeton< 1.5x✓SchlossP/B <= 0.80x (app cutoff)Valuation ReasonablenessOE Yield=-64.4%✗MungerP/E < 25 or Owner Earnings Yield > 5%P/E or FCF YieldFCF Yield=-364.0%✗PabraiP/E < 15 or FCF Yield > 10%P/B or P/E vs. Historical AverageP/B=0.4x✓MarksP/E < 15 or P/B < 2.0Discount to Intrinsic ValueN/A (negative normalized EPS)✗Marks>= 20% below intrinsic valuePrice / FCF per ShareN/A (negative FCF)✗Ackman<= 25Price vs. Trailing Low381% of trailing low ($0.58)✗Templeton<= 120% of trailing low (certified split-adjusted live window)Net income / market capitalization-1526.41%; #6116/6340 (top 96.5%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionPositive book equity / market capitalization+1.8143; #743/6449 (top 11.5%)✓AsnessTop 30% of eligible cross-sectionPrice / Diluted EPS✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)(EPS CAGR % + Dividend Yield %) / P/E✗Neff> 0.7 (Neff's published traditional edge)Price / Tangible Book Value per Share1.16x✗SchlossP/TBV <= 1.00x (app cutoff)Book Value per Share Change✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)Revenue / market capitalization✗OshaughnessyTop 10% of eligible cross-section(Operating cash flow - capex) / market capitalization-364.01%; #4305/4519 (top 95.3%)✗OshaughnessyTop 10% of eligible cross-sectionTrailing six-month price return through the evaluation date-48.00%; #5082/6202 (top 81.9%)✗OshaughnessyTop 10% of eligible cross-section - Cash Flow0% pass✓ 1✗ 11▾
No clean pass — all 10 investors flag at least one cash flow criterion
Free Cash Flow Proxy$-3.9M✗BuffettPositive and growingFCF Positive and Growing$-3.8M✗LynchPositive and growingOperating Cash Flow$-3.8M✗PiotroskiCFO > 0(CFO / Total Assets) vs ROACFO/Assets=-18.66%, ROA=-19.62%✓PiotroskiCFO/Assets > ROAPrice / (CFO / Shares)N/A (negative CFPS)✗Dreman< 8xP/E or FCF YieldFCF Yield=-364.0%✗PabraiP/E < 15 or FCF Yield > 10%FCF Positive0/5 years FCF positive✗MarksPositive FCF in majority of recent years(OCF - CapEx) / Market Cap-62.4%✗Ackman>= 4%Price / FCF per ShareN/A (negative FCF)✗Ackman<= 25Positive Operating Cash Flow frequency0/8 years positive✗SleepPositive OCF in >= 70% of available yearsOperating Cash Flow - Capital Expenditures$-3.8M✗Neff> $0 (app proxy for a strong fundamental case)(Operating cash flow - capex) / market capitalization-364.01%; #4305/4519 (top 95.3%)✗OshaughnessyTop 10% of eligible cross-section - Growth0% pass✗ 13▾
All 8 investors flag NXTS's growth
EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)✗Graham>= 33% growthBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passInventory Growth vs Revenue Growth✗LynchInventory growth < Revenue growthEPS Growth Direction$-0.05 (2018) -> $-8.61 (2025)✗DremanPositive over recent yearsEPS CAGR✗Dreman> 5% annualizedPositive Net Income Frequency0/8 years positive✗MarksPositive net income in >= 7 of last 10 years3yr Median Revenue Growth-26.7%✗Ackman>= 5%Positive EPS Growth Frequency1/5 years with positive EPS growth✗AckmanPositive EPS growth in >= 3 of last 5 years5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Revenue growth vs. gross and operating margin trend✗SleepRevenue rising; gross margin flat or falling; operating margin holding5-year Revenue CAGR✗SleepCAGR > 7%3-5 Year Diluted EPS CAGR✗Neff7%-20% annualized - Profitability6% pass✓ 3✗ 32▾
15 of 16 flag NXTS's profitability — Graham, Buffett, Lynch +12 more
Positive EPS (10 years)2/9 years positive✗GrahamPositive EPS every year for 10 yearsEPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)✗Graham>= 33% growthNet Income Positive (10+ years)0/9 years positive✗BuffettPositive every year for 10+ yearsROE (up to 5-year arithmetic mean)-81.5%✗Buffett> 15% arithmetic mean (app rule)Operating Margin (10-yr trend)-1563.3% (latest)✗BuffettStable or rising over 10 yearsFree Cash Flow Proxy$-3.9M✗BuffettPositive and growingEarnings Variance (10-yr CoV)12.43✗BuffettCoV < 0.3Retained Earnings Effectiveness✗Buffett$1 retained -> > $1 market value createdBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passROE-841.3%✗Lynch> 15%EBIT / Enterprise ValueN/A (EV <= 0)✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=N/A (EV <= 0), ROC=-546.5%✗GreenblattBoth EY > 10% and ROC > 25%Net Income / Total Assets-19.62%✗PiotroskiROA > 0ROA Change YoY-95.02% -> -19.62% (delta: +75.40%)✓PiotroskiCurrent ROA > Prior ROA(CFO / Total Assets) vs ROACFO/Assets=-18.66%, ROA=-19.62%✓PiotroskiCFO/Assets > ROAGross Margin Change YoY✗PiotroskiImproved YoYPre-Tax Income / Revenue✗Dreman>= 8%Net Income / Shareholders' Equity-841.3%✗Dreman> 12%Margin of SafetyP/B=0.4x✓PabraiP/B < 1.5 or P/E < 15Return on Equity-78.3% (3-yr avg)✗AkreROE > 20% (3-year avg)Discount to Intrinsic ValueN/A (negative normalized EPS)✗Marks>= 20% below intrinsic valuePositive Net Income Frequency0/8 years positive✗MarksPositive net income in >= 7 of last 10 yearsOperating Income / Revenue✗Ackman>= 15%Net Income / Shareholders Equity-841.3%✗Ackman>= 15%5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Operating Margin Trend✗TempletonNon-negative operating-margin trend over 3 yearsRevenue growth vs. gross and operating margin trend✗SleepRevenue rising; gross margin flat or falling; operating margin holdingNet income / market capitalization-1526.41%; #6116/6340 (top 96.5%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionGross profit / total assets✗AsnessTop 30% of eligible cross-sectionNet income / positive book equity-841.31%; #5148/5226 (top 98.5%)✗AsnessTop 30% of eligible cross-sectionNegative 5-year standard deviation of ROA-0.2807; #4551/5884 (top 77.3%)✗AsnessTop 30% of eligible cross-section3-5 Year Diluted EPS CAGR✗Neff7%-20% annualizedPositive Diluted-EPS Years2/8 years positive✗Schloss>= 70% positive over 5-10 observed years (app rule) - Verdicts7% pass✓ 1✗ 13▾
Split decision: 13 FAIL · 2 NEUTRAL · 1 PASS
Overall verdict✗GrahamFAIL (2/9)✗BuffettFAIL (0/9)✗LynchFAIL (0/7)•GreenblattNot ranked✓PiotroskiPASS (F-Score 5)✗DremanFAIL (2/11)✗MungerFAIL (1/4)✗PabraiFAIL (1/3)✗AkreFAIL (0/6)✗MarksFAIL (1/5)✗AckmanFAIL (1/9)✗TempletonFAIL (3/8)✗SleepFAIL (1/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (1/6)✗SchlossFAIL (3/7)•OshaughnessyNEUTRAL (Not ranked) - Efficiency25% pass✓ 3✗ 8▾
6 of 8 flag NXTS's efficiency — Buffett, Greenblatt, Piotroski +3 more
Current Ratio3.72✓Graham>= 2.0ROIC (3-5 yr avg)-52.7%✗Buffett> 10%ROIC - WACC-62.7%✗BuffettPositive (WACC = 10%)EBIT / (NWC + Net Fixed Assets)-546.5%✗Greenblatt> 25%Current Ratio Change YoY3.87 -> 4.19✓PiotroskiIncreased YoYRevenue / Total Assets Change YoY✗PiotroskiImproved YoYCurrent Assets / Current Liabilities3.72✓Dreman> 1.5Return on Invested Capital-235.8%✗Munger> 15%ROIC (high and growing)FY2023: ROIC=unavailable; FY2024: ROIC=-50.7%; FY2025: ROIC=-18.9%✗AkreLatest 3 consecutive FYs: ROIC > 15% in eachReinvestment Rate x ROICN/A (non-positive net income)✗AkreReinvestment Rate * ROIC > 10%ROIC (5-year)0/3 years above 12% (latest -18.9%)✗SleepROIC > 12% in a majority of years - Debt & Leverage33% pass✓ 6✗ 9▾
8 of 12 flag NXTS's debt & leverage — Graham, Buffett, Lynch +5 more
Total Debt / Shareholders' Equity0.91✗Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00xLT Debt vs Net Current Assets✗GrahamLT Debt <= Net Current AssetsDebt/Equity & Interest CoverageD/E: 0.11, IC: -54.9x✗BuffettD/E < 0.5 AND Interest Coverage > 5xTotal Debt / Equity0.91✗Lynch< 0.33Cash - Long-term Debt✗LynchPositive preferredLT Debt / Total Assets Change0.00% -> 0.00%✓PiotroskiDecreased YoYCurrent Assets / Current Liabilities3.72✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)Debt Levels0.91✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3Interest Coverage & Debt/EBITDAIC=-54.9x, D/EBITDA=N/A✗MarksInterest Coverage > 3x; Debt/EBITDA < 4xTotal Debt / Shareholders Equity0.91✓Ackman<= 1.0Negative debt-to-equity (higher means less debt)-0.9129; #3117/4210 (top 74.0%)✗AsnessTop 30% of eligible cross-section
Business & financials
Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.
Company Profile
Financial Snapshot
Shareholder Return
Fiscal 2025
Retired 52.6% of shares last year, 7.2% over two.
- Buybacks
- —
- Dividends
- —
Company Financials
Latest TTM and quarters alongside annual years
TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.
The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.
| Metric | TTM · 2026-06-30 2025-07-01 – 2026-06-30 Sources · derived quarter valuesDerived from cumulative filings: gross profit, operating cash flow, depreciation amortization, net income, operating income, ebit, capex. | Q2 FY 2026 2026-04-01 – 2026-06-30 Sources · derived quarter valuesDerived from cumulative filings: operating cash flow, depreciation amortization, capex. | Q1 FY 2026 2026-01-01 – 2026-03-31 Sources | FY 2025Sources
| FY 2024Sources
| FY 2023Sources
| FY 2022Sources
| FY 2021Sources
|
|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.0Mcurrent | -- | -- | $24.5Mest. | $1.8Best. | $1.2Best. | $9.8Best. | $20.8Best. |
| Revenue | -- | -- | -- | -- | $210.0K↓20% | $263.4K↓33% | $394.0K↓10% | $438.1K |
| Operating Income | -$10.9M↓81% | -$1.9M↑34% | -$8.2M↓1229% | -$4.2M↓29% | -$3.3M↑57% | -$7.6M↓30% | -$5.8M↓24% | -$4.7M |
| Net Income | -$16.0M↓72% | -$11.1M↓147% | -$6.6M↓452% | -$4.0M↑23% | -$5.2M↑20% | -$6.5M↓14% | -$5.7M↓19% | -$4.8M |
| EPS (Diluted) | -- | $-13.66↓7489% | $-10.74↓2654% | $-8.61↓867% | $-0.89↓116% | $5.43↓50% | $10.85↑627% | $-2.06 |
| Gross Margin | — | — | — | — | 21.4%↓73% | 79.0%↑32% | 59.8%↓13% | 69.0% |
| Operating Margin | — | — | — | — | -1563.3%↑46% | -2876.5%↓95% | -1477.1%↓38% | -1073.5% |
| ROE | -841.3%↓419% | — | — | -25.0%↑77% | -109.3%↓9% | -100.6%↓3% | -98.2%↓32% | -74.4% |
| Total Debt | $1.7M↑43% | $1.7M↑43% | $1.7M↑52% | $1.7M↑368% | $365.0K | -- | -- | $8.4K |
| Shareholders' Equity | $1.9M↓67% | $1.9M↓67% | $13.0M↑229% | $16.0M↑237% | $4.7M↓27% | $6.5M↑11% | $5.8M↓10% | $6.5M |
| Current Ratio | 3.72↓21% | 3.72↓21% | 4.73↑6% | 4.19↑8% | 3.87↓45% | 7.02↓20% | 8.77↑13% | 7.76 |
| Debt / Equity | 0.91↑333% | 0.91↑333% | 0.13↓54% | 0.11↑39% | 0.08 | — | — | 0.00 |
| Operating Cash Flow | -$4.4M↓63% | -$539.0K↓2% | -$1.4M↓75% | -$3.8M↓11% | -$3.4M↓6% | -$3.2M↑37% | -$5.1M↓24% | -$4.1M |
| Free Cash Flow | -- | -$540.0K | -$1.5M | -$3.8M | -- | -- | -$5.1M↓23% | -$4.2M |
Score history
Historical Score Timeline
Industry peers
Industry Peers
Similar companies in Chemicals
NXTS vs Peers — Financial Grading
| Company | Market Cap | Price | Revenue | Net Income | ROE | D/E | Op. Margin | Curr. Ratio | Graham | Buffett | Lynch | Greenblatt | Piotroski | Dreman |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EIDP, Inc.CTA-PB | $46.8B | $54.21 | — | — | — | — | — | — | 2/9 | 5/9 | 2/7 | 0/3 | F-Score 1 | 4/11 |
| CF Industries Holdings, Inc.CF | $18.3B | $125.09 | $7.1B | $1.8B | 37.2% | 0.66 | 32.5% | 3.37 | 3/9 | 4/9 | 5/7 | 3/3 | F-Score 8 | 8/11 |
| RPM INTERNATIONAL INC/DE/RPM | $13.2B | $103.73 | $7.9B | $661.4M | 20.0% | 0.77 | — | 1.68 | 3/9 | 2/9 | 3/7 | 1/3 | F-Score 6 | 7/11 |
| Element Solutions IncESI | $8.0B | $33.08 | $2.6B | $190.8M | 7.1% | 0.61 | 13.4% | 3.68 | 2/9 | 2/9 | 1/7 | 1/3 | F-Score 5 | 6/11 |
| NEWMARKET CORPNEU | $6.5B | $709.19 | $2.7B | $418.7M | 23.5% | 0.50 | 20.0% | 2.53 | 4/9 | 6/9 | 2/7 | 1/3 | F-Score 5 | 5/11 |
| HEXCEL CORP /DE/HXL | $6.0B | $79.46 | $1.9B | $109.4M | 8.7% | 0.79 | 9.1% | 2.26 | 2/9 | 2/9 | 3/7 | 0/3 | F-Score 6 | 4/11 |
| ICL Group Ltd.ICL | $5.8B | $4.52 | $7.2B | $226.0M | 3.8% | 0.46 | 8.1% | 1.33 | 5/9 | 4/9 | 2/7 | 0/3 | F-Score 4 | 5/11 |
| BALCHEM CORPBCPC | $5.5B | $173.14 | $1.0B | $154.8M | 12.3% | 0.13 | 20.2% | 2.07 | 2/9 | 4/9 | 2/7 | 1/3 | F-Score 9 | 5/11 |